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Highly sensitive detection of small, deep tumors for early di-
agnosis and surgical interventions remains a challenge for
conventional imaging modalities. Second-window near-infrared
light (NIR2, 950–1,400 nm) is promising for in vivo fluorescence
imaging due to deep tissue penetration and low tissue autofluo-
rescence. With their intrinsic fluorescence in the NIR2 regime and
lack of photobleaching, single-walled carbon nanotubes (SWNTs)
are potentially attractive contrast agents to detect tumors. Here,
targeted M13 virus-stabilized SWNTs are used to visualize deep,
disseminated tumors in vivo. This targeted nanoprobe, which uses
M13 to stably display both tumor-targeting peptides and an SWNT
imaging probe, demonstrates excellent tumor-to-background uptake
and exhibits higher signal-to-noise performance compared with visi-
ble and near-infrared (NIR1) dyes for delineating tumor nodules. De-
tection and excision of tumors by a gynecological surgeon improved
with SWNT image guidance and led to the identification of sub-
millimeter tumors. Collectively, these findings demonstrate the
promise of targeted SWNT nanoprobes for noninvasive disease
monitoring and guided surgery.
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In clinical oncology, in vivo fluorescence imaging has emergedas a valuable tool for improving diagnosis, staging tumors,
monitoring response to therapy, and detecting recurrent or re-
sidual disease. Compared with existing imaging modalities, fluo-
rescence imaging offers a low-cost, portable, and safe alternative
(i.e., nonionizing radiation), with key advantages including real-
time imaging, superior resolution, and high specificity for small
tumor nodules during diagnostic and intraoperative surgical pro-
cedures (1, 2). Although efforts have focused on using visible and
short near-infrared (NIR1, 650–900 nm) wavelength fluorescent
dyes as contrast agents for delineating tumor margins in both
preclinical cancer models (2, 3) and human patients (4), these
agents are suboptimal for noninvasive, reflectance-based imaging
due to limited penetration depth (3–5 mm) and high tissue auto-
fluorescence. During intraoperative surgery, these dyes may addi-
tionally undergo photobleaching, thereby reducing the ability
of the surgeon to readily locate and resect tumors. Alternative
approaches to specifically permit noninvasive imaging and lim-
ited photobleaching would be highly desirable for diagnostic and
surgical applications.
Single-walled carbon nanotubes (SWNTs) hold great promise
as fluorescence imaging agents due to the large interband dif-
ference between their excitation and emission wavelengths, result-
ing in minimal spectral overlap and tissue autofluorescence. In
particular, the low tissue autofluorescence observed with SWNTs
greatly enhances target-to-background ratios (TBRs) necessary
for improved detection of small tumor nodules in confined
anatomic regions. SWNT emission at longer wavelengths in the
near-infrared second window (NIR2, 950–1,400 nm) results in less
optical scattering and deeper tissue penetration compared with
shorter wavelength visible and NIR1 imaging agents. Simulations
(5) and experimental results (6) suggest the greatest tissue pene-
tration depth is achieved in the NIR2 regime, which further sup-
ports the potential value for use of SWNTs for biological imaging
applications. Additionally, unlike visible and near-infrared dyes,
well-functionalized SWNTs are less susceptible to photo-
bleaching or quenching effects (7), which make them attrac-
tive for continuous, long-term imaging required during many
surgical procedures. Previously, we have demonstrated that M13
bacteriophage-stabilized SWNTs can target s.c. prostate tumors
in preclinical models for fluorescence imaging in the second
optical window (8). SWNTs have also been used for vascular and
deep tissue fluorescence imaging (9). Importantly, M13 serves
as a scaffold to couple both targeting and imaging moieties while
allowing them to retain their functionalities (10); in comparison,
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more prevalent nanoparticle systems directly conjugated with
targeting ligands may require optimization of ligand density for
effective targeting (11, 12). Also, the identification of tissue-
targeting peptides via phage display has been valuable for
enhancing nanoparticle trafficking in vivo (13, 14). However, to
date, there has been no report of an affinity-targeted, fluores-
cence imaging agent capable of noninvasive imaging and guiding
diagnosis for surgical resection.
Here we report an M13-stabilized SWNT probe that selec-
tively targets Secreted Protein, Acidic and Rich in Cysteines
(SPARC)-expressing tumor nodules in an orthotopic mouse
model of human ovarian cancer. Ovarian cancer remains a ma-
jor health care problem for women. Annually, 225,000 women
worldwide are diagnosed with epithelial ovarian cancer (EOC)
and ∼140,000 women die as a result (15). Although women with
early-stage ovarian cancer [International Federation of Gyne-
cology and Obstetrics (FIGO) stage I/II] can be cured, advanced-
stage ovarian cancer (FIGO III/IV) remains considerably more
difficult to treat. Unfortunately, 80% of women with EOC have
metastatic disease at the time of diagnosis, and many undergo
a treatment regimen of surgery and chemotherapy. Our study
focused on ovarian cancer because clinical evidence indicates
that optimal surgery can significantly prolong the median overall
survival of patients as well as reduce disease morbidity (16).
Using the NIR2 emission of these fluorescence probes, we de-
termine the detection limit of labeled tumors and their TBRs.
We demonstrate that this SWNT-based probe detects tumors
that were missed when either visible or NIR1 dyes were used,
thereby aiding the discovery of smaller tumors during surgery.
Collectively, our results highlight the potential for affinity-tar-
geted NIR2 fluorescence probes to monitor disease processes
such as cancer with enhanced sensitivity compared with current
state-of-the-art optical probes.
Results
Characterization of the M13-Stabilized SWNT Probe. The imaging
probe [SPARC binding peptide (SBP)–M13–SWNT] consists
of three fundamental components: the SBP, M13 virus, and
SWNTs (Fig. 1A). The filamentous M13 virus (6 nm diameter,
880 nm length) is genetically modifiable such that peptides can
be incorporated for display on the various coat proteins of the
virus. By displaying peptides with varying affinities to materials
or biomolecules through an iterative panning and selective en-
richment process, M13 is well suited for diverse applications
including epitope mapping (17), ligand discovery against cells
and tissues (18), and binding and nucleation of materials (19,
20). The modularity of M13 can be further exploited to target
various biomarkers in cancers, highlighting its attractiveness as
a multifunctional probe. Previously, we used phage display to
identify a peptide along the p8 major coat protein of M13 that
binds and stabilizes SWNTs (20), while retaining the optical and
electronic properties of the nanotubes. Because M13 can be
genetically engineered to display 100% of fusion peptides, we
further engineered the p3 minor coat protein to display five
copies of a targeting peptide that binds SPARC (21). SPARC is
a matricellular protein highly expressed in certain subtypes of
breast, prostate, and ovarian cancer. SPARC overexpression has
been shown to enhance ovarian cancer cell proliferation, in-
vasion, and metastasis. High levels of SPARC expression have
been associated with late stages of ovarian carcinoma and cor-
related with poor clinical prognosis (22), suggesting its relevance
as a clinical biomarker. Collectively, these traits have been taken
into account in the design of this genetically engineered NIR2
probe in order to enable the localization, detection, and surgical
excision of ovarian tumors, as outlined in the schematic pre-
sented in Fig. 1A.
To ensure that our probe retained its functionality following
synthesis, we examined the optical properties of SBP–M13–
SWNTs. Compared with unmodified SWNTs dispersed in so-
dium cholate, complexed SBP–M13–SWNTs exhibited similar
optical absorbance that was consistent across multiple batches
(Fig. 1B and SI Appendix, Fig. S1). Previously, photoluminescence
(fluorescence) mapping of the excitation and emission wave-
lengths of SBP–M13–SWNTs suggests M13-stabilized SWNTs
retain their fluorescent properties; nondispersed, aggregating, or
bundled SWNTs would quench and not fluoresce and thus not
appear in the fluorescence mapping (8).
To establish their use for in vivo applications, we validated the
stability of SBP–M13–SWNTs in blood and ascites and at dif-
ferent pH values by measuring the fluorescence over 24 h using
a custom-built small-animal NIR2 fluorescence imager (8). SBP–
M13–SWNTs retain fluorescence at various dilutions in the
blood and ascites fluid from the peritoneal cavity (SI Appendix,
Figs. S2 and S3, respectively), and we did not observe quenching
of the probe. Previous reports indicate that exposed SWNTs in
solution will adsorb serum proteins on their sidewall and sub-
sequently lose fluorescence (8, 23). Here, we observe no loss of
fluorescence intensity, indicating the probes are well solubilized
by M13 and highly stable for in vivo imaging applications. In
addition, the probe is fluorescently stable across a broad pH
range, from 4.5 to 8.5 (SI Appendix, Fig. S4), suggesting the
Fig. 1. Characterization of tumor-targeting SBP–M13–SWNT probe. (A) Sche-
matic illustrating association with ovarian tumor nodules for noninvasive
detection by NIR2 fluorescence and surgical excision. (B) Absorbance spectra of
SWNTs in sodium cholate and as SBP–M13–SWNT probe. (C) In vitro sensitivity
of SBP–M13–SWNT fluorescence in ovarian cancer cell culture. n = 3 per group.
Error bars represent SE. (D) Photobleaching fluorescence decay of FITC and
SBP–M13–SWNTs under continuous excitation. Error bars represent SD. (E)
Pharmacokinetic circulation study of SBP–M13–SWNT administered i.v. (IV) and
intraperitoneally (IP). n = 3 per timepoint. Errors bars represent SE.


















probes will be stable in the vascular and lymphatic systems and
the peritoneal cavity and for cellular uptake. We also confirmed
the targeted probes are not acutely cytotoxic to primary human
endothelial cells and ovarian carcinoma cell line 8 (OVCAR8)
(SI Appendix, Figs. S5 and S6, respectively), which builds upon
previous studies on cell-type dependence of nanomaterial toxicity
(24) and underscores their potential for in vivo imaging applications.
We next examined the sensitivity of the probe in terms of its
capacity to target OVCAR8 ovarian cancer cells in vitro. Serial
10-fold dilutions of OVCAR8 cells were incubated with
SBP–M13–SWNT for 24 h, and cell lysates were collected.
Measuring the fluorescence intensity of the SBP–M13–SWNT
incubated cells, we observed that as few as ∼10,000 cells in-
cubated with SBP–M13–SWNT exceeded the minimum level
of detection (Fig. 1C).
To test SBP–M13–SWNTs for risk of photobleaching, we ex-
posed them to an 808-nm laser for a continuous, 30-min period and
measured fluorescence intensity in 5-min intervals up to 30 min
postirradiation. No appreciable loss of fluorescence of SBP–
M13–SWNTs was observed during this period. However, the
intensity of fluorescein isothiocyanate (FITC), a fluorescein de-
rivative that has been used to molecularly image and guide
intraoperative resection of ovarian tumors in humans (4), expo-
nentially decreased in response to the same light exposure kinetics
(Fig. 1D). The observations that SWNTs do not photobleach and
maintain their optical properties illustrate their potential to assist
surgeons in visualizing tumors during resection.
Another potential advantage of SWNT-based imaging com-
pared with FITC-based imaging is the potential to detect tumors
located at greater depths in the body. To investigate the depth of
detection that can be achieved with our probe, we harvested
ovarian tumors that had been treated with SBP–M13–SWNTs
and imaged the small tumor fragments (∼1-mm diameter) at
various depths within a tissue “phantom” construct, which
mimics the optical properties of human tissue. Using our NIR2
fluorescence reflectance imaging system (8), we could detect
SWNT-containing tumors to depths as great as 9.7–18.2 mm
(SI Appendix, Fig. S7). To our knowledge, this is the best
reported quantifiable tumor depth using reflectance imaging,
relative to previously reported values (3). By permitting deeper
imaging, SBP–M13–SWNT therefore offers the potential for
noninvasive detection before surgery and improved resection
of tumors during surgery.
In Vivo Characterization of the SBP–M13–SWNT Probe. Having dem-
onstrated in vitro stability and fluorescence of SBP–M13–SWNTs,
we next characterized their in vivo properties in an orthotopic
model of ovarian cancer. The OVCAR8 human cell line was
used to create the orthotopic model, as it overexpresses SPARC,
as confirmed by ONCOMINE (25) analysis and immunohisto-
chemistry (SI Appendix, Fig. S8). To compare routes of admin-
istration, tumor-bearing animals were injected intraperitoneally
or i.v., and the circulating probe concentration was monitored via
SWNT fluorescence in the blood. The i.v.-administered SBP–
M13–SWNTs reached a peak concentration in the circulation
∼10 min after injection, and circulating levels became negligible
after 150 min (Fig. 1E). Notably, SBP–M13–SWNTs injected
intraperitoneally led to negligible elevations in blood-borne
SWNT fluorescence for at least 24 h, suggesting that the majority
of SBP–M13–SWNTs remain in the peritoneum postinjection
(Fig. 1E). This finding was verified by the observation that, fol-
lowing a transient increase in NIR2 fluorescence in the perito-
neum, the overall intensity in this location stabilizes for periods
up to 24 h following injection (Fig. 2 A and B). Lastly, we studied
the biodistribution of SBP–M13–SWNTs administered into the
peritoneal cavity of tumored mice (SI Appendix, Fig. S9). The
accumulation of SBP–M13–SWNTs was greatest in tumors at
days 1 and 7 postinjection, with additional signal observed in
liver, spleen, kidney, and peritoneum in the vicinity of the in-
jection site. At day 7 postinjection, the lowest signals observed
were in heart and lung tissue, supporting limited systemic ex-
posure of SBP–M13–SWNT after i.p. administration. Impor-
tantly, analysis of serum from tumor-bearing animals following
the administration of SBP–M13–SWNTs into the peritoneal
cavity revealed no evidence of systemic hepatic, renal, metabolic,
or hematologic acute toxicities within the first week following
administration (SI Appendix, Fig. S10).
Improved Signal-to-Noise Performance in Vivo Using SBP–M13–SWNT
in the NIR2 Wavelength Regime. Signal-to-noise behavior is a criti-
cal parameter for sensitive detection of tumors. To directly
compare the signal-to-noise ratios between SWNTs and dyes
in the NIR1 or visible regimes, SBP–M13 viruses were either
complexed to SWNTs or conjugated with AlexaFluor750 dye
(SBP–M13–AF750) or FITC (SBP–M13–FITC). Probes were
then combined and added in fivefold excess of their minimum
detection limits to mice bearing disseminated tumors. Noninvasive
images were acquired through the fully intact skin of tumor-
bearing animals (Fig. 2C), and fluorescence intensities from
tumors in the peritoneal cavity, muscle, and background were
determined. The tumor-to-muscle ratio of SBP–M13–SWNTs was
5.5 ± 1.2 (mean ± SD), which was significantly higher than ratios
calculated for SBP–M13–AF750 (3.1 ± 0.42) and SBP–M13–FITC
(0.96 ± 0.10) (Fig. 2D). The TBR (i.e., intensity of tumor to image
Fig. 2. Noninvasive tumor imaging with SBP–M13–SWNTs. (A) Representa-
tive whole-abdomen NIR2 imaging series following i.p. administration of
SBP–M13–SWNTs. (Inset) Surgically excised tumor nodule (denoted by red
arrow) observed 24 h postinjection of SBP–M13–SWNTs. (B) NIR2 fluores-
cence intensity in the abdomen of tumor-bearing animals following IP ad-
ministration of SBP–M13–SWNTs up to 24 h postinjection (n = 6; error bars
represent SE). (C) Noninvasive imaging of ovarian tumors using SBP–M13
conjugated to SWNTs (NIR2), AlexaFluor750 (NIR1), and FITC (Visible) (top to
bottom). Arrows in the SWNTpanel denote nodules visible only by SWNTs (n= 3
animals). (D and E) Tumor-to-muscle ratio and TBR from noninvasive images
obtained with SWNTs, AF750, and FITC (n = 3 per group; ***P < 0.001; *P < 0.05;
one-way ANOVA and Tukey posttests). Error bars, s.d. [Scale bar, 1 cm (A).]
13950 | www.pnas.org/cgi/doi/10.1073/pnas.1400821111 Ghosh et al.
background) achieved using SBP–M13–SWNTs was 134.9 ± 21.0,
which was a 24- and 28-fold improvement over SBP–M13–AF750
and SBP–M13–FITC, respectively (Fig. 2E). Importantly, as
highlighted by the arrows in Fig. 2C, tumor nodules not observed
in the visible and NIR1 channels were detectable in the NIR2
regime with SBP–M13–SWNTs, which highlights the sensitivity
of the SWNT probe and imaging system.
Selective and Affinity Targeting of SBP–M13–SWNT to Ovarian Tumors
in Vivo. Because many tumor nodules are implanted on the sur-
faces of peritoneal organs in this model, we also computed organ-
specific TBRs for tumor nodules on the liver, intestine, and
spleen. Representative photographs of organs containing tumor
implants on their surface with their corresponding NIR2 fluo-
rescent images are shown in Fig. 3A. The TBRs (i.e., ratio of
surface tumor nodule fluorescence relative to that observed in its
underlying organ) calculated for the liver, intestine, and spleen
were 4.6, 8.0, and 3.1, respectively (Fig. 3B), highlighting the
specificity of the probe toward tumor nodules compared with its
underlying organs.
The in vivo sensitivity of targeting conferred by the SBP was
assessed by injecting tumor-bearing animals with M13–SWNTs
expressing SBPs or untargeted M13–SWNTs. The NIR2 in-
tensities of excised tumor nodules and intestinal tissue of the
same animal were used to compute TBRs for the targeted and
untargeted probes. SBP–M13–SWNTs showed significant,
10-fold higher TBRs than untargeted M13–SWNTs, likely due
to a combination of improved targeting and reduced tissue
autofluorescence in the NIR2 window (Fig. 3C).
To verify the specificity of SBP–M13–SWNTs, we assessed the
SWNT-positive tumor nodules by immunohistochemistry. Stan-
dard hematoxylin and eosin (H&E) staining of SWNT-positive
tumor sections revealed histopathological features consistent with
ovarian tumor nodules, including a high nuclear-to-cytoplasmic
ratio, cellular crowding, a necrotic core, and a distinct architecture
from underlying organs (Fig. 3D). Interestingly, the liver exhibits
a fluorescent signal where no tumor nodule is visible by the eye,
and after biopsy of the indicated area, H&E staining indicated
pathology consistent with tumor nodules located on the liver (Fig.
3D, Upper). Additionally, immunohistochemical staining revealed
an enrichment of SPARC expression along the periphery of the
SWNT-positive tumor nodules (SI Appendix, Fig. S8). Finally, to
assess whether our probe specifically colocalizes with SPARC-
expressing regions of the tumor nodules, we administered
SBP–M13–SWNTs conjugated with AlexaFluor750 to tumor-
bearing mice and analyzed the excised tumor nodules by immuno-
fluorescence. In multiple nodules, SPARC was widely expressed,
with particularly strong expression at the tumor periphery (Fig. 3E,
Middle) in a pattern consistent with our immunohistochemical
staining described in SI Appendix, Fig. S8. The AF750-labeled
SBP–M13–SWNTs were similarly enriched at the tumor pe-
riphery (Fig. 3E, Bottom). These patterns are consistent with an
outside–in diffusion model limited both by the hydrodynamic ra-
dius and ligand interactions of SBP–M13–SWNTs with the
tumor nodule.
Image Guidance Using SBP–M13–SWNT Improves Surgical Resection
of Tumors. To assess the potential clinical utility of SBP–M13–
SWNTs for reduction of tumor burden, a gynecological surgeon
performed surgeries on orthotopic models of ovarian cancer that
were imaged at various points during the surgical procedures.
Approximately 15–25 min were spent on procedures in each ex-
periment, and tumor implants were predominantly distributed in
the bowel mesentery, peritoneal wall, subdiaphragmatic surfaces,
and surfaces of organs including the liver, spleen, pancreas, and
within the pelvic cavity. H&E-stained tissue sections were pre-
pared from all excised nodules and assessed by a pathologist. With
the exception of two non–tumor-containing mesenteric lymph
nodes, all tissues examined (n = 197) were positive for ovarian
tumor tissue, indicating an accuracy of 98.9% of our probe for
ovarian tumors. Surgery was first performed with preoperative
image guidance to assess whether this addition to the process
would be beneficial to the surgical procedure based on the dis-
tribution of excised tumor nodule sizes. A comparative analysis of
excised tumors revealed that a significantly higher number of
submillimeter tumor nodules were discovered in the image-guided
cohorts versus the non–image-guided cohorts (12 and 0 nodules,
respectively; SI Appendix, Fig. S11). Using image guidance, there
were also greater numbers of excised tumors from 1.3 to 3 mm;
however, there was no appreciable difference for larger tumors
(>3 mm) between image-guided and non–image-guided cohorts.
We additionally assessed the impact of performing surgery in a
serial manner, with an initial round of non–image-guided surgery,
followed by image acquisition and a second round of image-
guided surgery (Fig. 4A). We observed reduction of tumor
burden from non–image-guided surgery to image-guided surgery
Fig. 3. Specificity of SBP–M13–SWNTs for OVCAR8 tumor nodules in the ab-
dominal cavity. (A) Photographs and NIR2 fluorescence (10–50-ms exposure) of
tumor nodules implanted on several peritoneal organs. (B) Quantification of
nodule and organ-specific background for nodules present on the liver, in-
testine, and spleen (n = 8–11 nodules per organ; **P < 0.01; ****P < 0.0001;
two-tailed t tests). (C) Tumor-to-intestine ratio for targeted and untargeted
M13–SWNT probes. Intestinal tissue used for background intensity (+SBP, n = 6;
–SBP, n = 13; **P < 0.01; two-tailed t test). (D) Representative NIR2 fluorescence
and H&E staining of a positive nodule revealing characteristic tumor histology.
(E) Immunofluorescence staining reveals colocalization of M13–SBP–SWNTs
conjugated to AlexaFluor750 dye with SPARC expression in an NIR2-positive
nodule. [Scale bars, 10 mm (A), 10 mm (D, NIR2), 250 μm (D, H&E liver nodule),
125 μm (D, H&E nodules), 5 mm (E, NIR2), and 2.5 mm (E, SPARC, AF750–M13).]


















(Fig. 4B). We determined the TBR of overall tumor burden to
background muscle by region of interest analysis and confirmed
reduction of overall tumor burden due to image-guided re-
duction (Fig. 4C). Using both SWNT imaging (Fig. 4B) and
quantification of excised tumor nodule diameters, we observed
a greater number of submillimeter excised tumors in the groups
assisted by SWNT image guidance (30 versus 4 nodules;
Fig. 4 D and E). Overall, significantly more, smaller diameter
tumors were excised using SWNT-based image guidance as op-
posed to unguided surgeries (Fig. 4F).
Discussion
This study describes the development and use of a single fluo-
rescence imaging agent for high-contrast, detection and guidance
for surgical removal of disseminated ovarian tumors. NIR2-
emitting SWNT probes offer significantly improved signal-to-
noise performance compared with visible and near-infrared dyes
and detect tumors not visualized using the optical dyes. These
targeted, M13-stabilized SWNT probes assist surgical removal of
ovarian tumors with excellent sensitivity, as confirmed by sub-
sequent pathological examination. The probe is sensitive for
identifying tumor nodules located on several abdominal viscera,
the peritoneal wall, and the bowel mesentery. Importantly,
compared with fluorescent probes in the visible or NIR1 regimes,
the fluorescence of SWNTs is not limited by quenching, allowing
for long-term, continuous imaging. With the development of
advanced imaging platforms, surgeons may be able to visualize
tumors both before and throughout surgical procedures, thereby
significantly improving fluorescence-guided tumor resection.
This study demonstrates that surgery accompanied by image
guidance leads to identification and removal of smaller tumor
nodules. Although NIR2 images could not provide 3D localiza-
tion of the tumor implants, they provided information about the
sites of disease burden requiring closer surgical examination. Im-
aging of regions in which the surgeon was initially reluctant to
explore in an effort to minimize morbidity by risking excessive
blood loss, but were shown to harbor a positive NIR2 signal, often
led to the identification and excision of additional tumor nodules
missed on non–image-guided approaches. Although we did not
investigate longitudinal survival rates after image-guided surgery
due to surgical constraints in our small-animal models, the majority
of clinical evidence suggests that optimal surgery, currently defined
as the removal of tumors with diameters of 1 cm and larger, is
correlated with improved overall survival rates (16). SWNT-based
affinity probes may aid in surgical planning and resection to help
achieve a reduction in mortality rates in the future.
We achieve detection of submillimeter tumors with excellent
TBRs using M13-stabilized SWNTs, in part due to properties of
the particles that lead to low tissue scattering and minimal tissue
autofluorescence in the NIR2 optical window. In comparing
excised tumors with unaffected intestinal tissues as a background
measurement, we observed high TBRs of ∼112 using our
SPARC-targeted M13–SWNT probes. Following i.p. adminis-
tration, some uptake is observed using nontargeted SWNT
probes, which is most likely due to nonspecific binding inter-
actions or convective flow patterns present within the peritoneal
cavity. Whereas many nanoparticles include targeting peptides
conjugated directly to the nanoparticle, our nanoprobe takes
advantage of the genetically encoded M13 scaffold to spatially
uncouple the targeting peptide (SBP) from the imaging probe
(SWNT). This separation of targeting and imaging moieties
circumvents direct and excessive conjugation, which may abolish
the functionality of each component (11, 26); however, how this
spatial uncoupling affects both targeting and nanomaterial
functionality is an area requiring further study.
Fluorescence imaging in the second optical window offers the
promise of imaging at greater penetration depths (>3–5 mm)
with reduced optical scattering within the tissue. In comparing
the performance of visible, NIR1, and NIR2 probes, the M13–
SWNT probe achieved the highest tumor-to-muscle ratios and
TBRs, most likely due to less tissue absorbance and auto-
fluorescence in the NIR2 regime. In addition, we were able to
see tumors not observed in the visible and NIR channels, high-
lighting the improved tissue penetration and detection in the
NIR2 regime. Using our reflectance imaging system, we can
detect 1-mm-diameter tumors up to a maximal depth between
9.7 and 18.2 mm. To our knowledge, this represents the highest
reported depth of detection using fluorescence reflectance and is
also higher than previous reports that detected mammary tumors
labeled with activatable Cy5 probes (3). Future work to enhance
the fluorescence of M13–SWNTs using plasmonic nanomaterials
(27) and affinity targeting using other ligand–receptor inter-
actions including the folate receptor (4) may offer further
improvements on current limits of detection and resolution.
These longer wavelength-emitting probes will greatly aid in lo-
cating ovarian tumors confined to deep anatomical regions.
SBP–M13–SWNTs injected intraperitoneally colocalized with
stromal SPARC expression on the periphery of the ovarian tu-
mor nodules. Tumor nodules labeled with the probes exhibited
high signal with low background in the surrounding healthy tis-
sues, including liver, spleen, and intestine. These high organ-
specific TBRs contributed to more accurate surgical resection
of tumor nodules localized to the organ surfaces. Because our
probes can visualize the tumor margins, they have potential to
assist the surgeon in delineating tumors from healthy tissue for
improved resection of other solid tumors, as also demonstrated
by approaches using activatable peptides (3, 28) and dyes (2),
fluorescein conjugates (4), and multimodal nanoparticles (29).
The use of nanomaterials as clinical imaging probes is a rap-
idly evolving area. As new materials emerge from the com-
munity, their attractiveness for clinical applications is typically
Fig. 4. Surgical removal of tumors with SBP–M13–SWNT guidance. (A)
Schematic of serial surgical procedure. (B) Representative whole-abdomen
NIR2 images before injection of SBP–M13–SWNT, before surgery, after an
initial unguided surgery, and after subsequent SBP–M13–SWNT-guided
surgery. White arrow indicates an SWNT-positive nodule detected only
during image-guided surgery. (C) TBRs during surgery. Muscle from the hind
limb was used for background (**P < 0.01; ****P < 0.0001; two-tailed t tests;
error bars represent SE). (D) Photographs and NIR2 images of excised tumor
nodules following unguided and SWNT-guided surgery. (E) Histogram of
tumor diameters removed with and without guidance. (F) Dot plot of in-
dividual tumor nodule diameters excised with and without SWNT-guidance
(guided, n = 74; unguided, n = 146; **P < 0.01; two-tailed t test). [Scale bars,
1 cm (B), 1 cm (C, photograph), and 1 cm (C, NIR2).]
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informed first by their in vitro properties, then by their behav-
ior in animal models, and ultimately by their performance in
humans. In this context, M13–SWNT probes exhibit many de-
sirable in vitro properties such as solution stability, retention of
optical properties under various pH and physiological environ-
ments and under constant excitation, and the dual capability of
genetically encoding affinity ligands and solubilizing SWNTs.
The next step in assessing their attractiveness for clinical trans-
lation is to assess their performance in animal models. Thus, this
study explores the roles of targeting, acute biocompatibility via
i.p. delivery, and optical emission in NIR2 in a preclinical mouse
model of ovarian cancer. Our acute toxicity studies are consistent
with several other preliminary studies exploring the safety of
M13 and SWNTs, in that a panel of serum biomarkers were not
elevated (30–33). Collectively, we believe these findings suggest
that these materials warrant further consideration for clinical
translation, which would include the development of instruments
for real-time imaging, outcomes research such as survival studies
in preclinical models, and rigorous safety evaluation through
the National Characterization Laboratory (National Cancer In-
stitute) and others to assess long-term trafficking and clearance
of these materials as well as chronic toxicity studies.
Although in this study we use SWNTs for fluorescence imag-
ing, others have demonstrated their utility as carriers for thera-
peutic cargoes (reviewed in ref. 34) as well as photothermal
ablative therapy (35). We have begun to explore the utility of
SBP–M13–SWNTs for in vivo heating of the tumor microenvi-
ronment to assess their potential as sensitizing agents to multi-
modal imaging and therapeutic agents.
To advance our findings closer to clinical translation, new
instrumentation will be required to allow for real-time intra-
operative guidance and 3D tomography for quantitative analysis
and more accurate localization of tumors. Simulations suggest
that at near-infrared wavelengths that define the NIR2 window,
SWNT-based probes may be detectable at depths up to 10 cm on
improved imaging platforms, highlighting the potential utility of
these particles in human subjects (36). This new platform would
allow for real-time, noninvasive imaging and processing for
visualization of tumors during tumor staging, presurgical plan-
ning, and procedures. Coupling improved instrumentation with
probe development will greatly improve the ability to detect tumors
at earlier stages. The instrumentation should also be compatible
with other NIR2 window optical probes as they are developed. Early
detection of smaller tumors may also provide fundamental insights
into tumorigenesis and disease progression, as well as allow clinicians
to better monitor therapeutic responses and recurrence of disease.
Materials and Methods
All materials are provided in SI Appendix, SI Materials and Methods. In vitro
and in vivo characterization of the SBP–M13–SWNT probe, including optical
properties, stability, detection sensitivity, biodistribution, and serum chem-
istry assays, are described in detail in SI Appendix, SI Materials and Methods.
Tumor induction procedure, fluorescence imaging, and analysis of SBP–M13–
SWNT targeting in vivo and ex vivo are detailed in SI Appendix, SI Materials
and Methods. Comparison of noninvasive imaging between SBP–M13–SWNT
with visible and NIR1 imaging probes and image-guided surgeries is de-
scribed in SI Appendix, SI Materials and Methods.
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